

**To:** [redacted] @rivm.nl; [redacted] @rivm.nl;  
 [redacted] @ggdghor.nl; [redacted] @ggdghor.nl; [redacted] @ggdghor.nl; [redacted] @ggdghor.nl;  
 [redacted] @berenschot.nl; [redacted] @berenschot.nl; [redacted] @ggdghor.nl; [redacted] @ggdghor.nl;  
 [redacted] @ggdghor.nl; [redacted] @ggdghor.nl; [redacted] @oaktrees.nl; [redacted] @oaktrees.nl;  
 [redacted] @minvws.nl; [redacted] @minvws.nl; [redacted] @actiz.nl; [redacted] @actiz.nl;  
 [redacted] @zorgthuisnl.nl; [redacted] @zorgthuisnl.nl; [redacted] @zorgthuisnl.nl; [redacted] @zorgthuisnl.nl;  
 [redacted] @vgn.nl; [redacted] @vgn.nl; [redacted] @wispa.nl; [redacted] @wispa.nl; [redacted] @rivm.nl;  
 [redacted] @rivm.nl; [redacted] @rivm.nl; [redacted] @rivm.nl; [redacted] @rivm.nl;  
 [redacted] @denederlandseggz.nl; [redacted] @denederlandseggz.nl; [redacted] @actiz.nl; [redacted] @actiz.nl;  
 [redacted] @rivm.nl; [redacted] @rivm.nl; [redacted] @minvws.nl; [redacted] @minvws.nl;  
 [redacted] @minvws.nl; [redacted] @minvws.nl; [redacted] @rivm.nl; [redacted] @rivm.nl;  
 [redacted] @rivm.nl; [redacted] @vgn.nl; [redacted] @vgn.nl; [redacted] @venvn.nl;  
 [redacted] @minvws.nl; [redacted] @minvws.nl; [redacted] @minvws.nl; [redacted] @minvws.nl;  
 [redacted] @bvkgz.nl; [redacted] @bvkgz.nl; [redacted] @valente.nl; [redacted] @valente.nl;  
 [redacted] @venvn.nl; [redacted] @venvn.nl; [redacted] @minvws.nl;  
 [redacted] @revalidatie.nl; [redacted] @revalidatie.nl

**From:** [redacted] 5.1.5

**Sent:** Fri 3/12/2021 10:57:53 AM  
**Subject:** Materialen communicatie AstraZeneca: spreeklijn  
**Received:** Fri 3/12/2021 11:02:00 AM

Beste regiegroepleden  
 Ter aanvulling op de vorige mail de VWS woordvoeringslijn mbt vaccinatie met AstraZeneca.

Groet,  
 [redacted] 5.1.2e

[redacted]

Rijksinstituut voor Volksgezondheid & Milieu (RIVM)  
<https://www.rijksoverheid.nl/onderwerpen/coronavirus-vaccinatie>  
<https://www.rivm.nl/coronavirus-covid-19/professionals>

[redacted]

2 - 3

Dubbel